Improved sensitivity for detection of breast cancer by combination of miR-34a and tumor markers CA 15-3 or CEA

Abstract

BackgroundMicroRNAs biomarkers have shown value for diagnosis and prognosis of various cancers. Combination with established tumor markers has rarely been done.ResultsBreast cancer patients had significantly higher serum RNA loads (AUC 0.665), lower miR-34a (AUC 0.772), higher CEA and CA 15-3 levels (AUCs 0.717 and 0.721) than healthy controls. miR-34a correlated with tumor stage and hormone receptor status. There was no significant difference between groups for all other miRNAs. Combination of miR-34a with CEA or CA 15-3 led to improved AUCs of 0.844 and 0.800, respectively. Sensitivity of miR-34a and CA 15-3 reached 56.1% at 95% specificity. When compared with benign breast diseases, combination of miR-34a (AUC 0.719) and CEA (0.623) or CA 15-3 (0.619) resulted in improved performances (0.794 and 0.741). Sensitivity of miR-34a and CA 15-3 reached 53.7% at 95% specificity.ConclusionWhile miR-34a provides valuable information for diagnosis and staging, combination with tumor markers CA15-3 or CEA improves the sensitivity for breast cancer detection.Patients and MethodsThe diagnostic relevance of the miR-21, miR-34a, miR-92a, miR-155, miR-222 and miR-let-7c was tested in sera of 103 individuals (55 breast cancer, 20 benign breast diseases, 28 healthy controls). MiRNAs were detected by quantitative rt-PCR after extraction and reverse transcription. Cel-miR-39 and miR-16 were used for normalization. Established tumor markers CEA, CA 15-3, CA 19-9 and CA 125 were measured by automatized immunoassays. Diagnostic performance was tested by areas under the curve (AUC) of receiver operating characteristic (ROC) curves and sensitivities at 90% and 95% specificity.

Genetic and epigenetic modifications of adiponectin gene: Potential association with breast cancer risk

“…Well known BC tumor markers such as CEA and CA15‐3 are only valuable in late stages, may be helpful for the assessment of the therapeutic response and/or the detection of recurrence. In early stages, their sensitivity is limited …”

The circulating level of Non-coding RNA for breast cancer diagnosis

“…Currently, 30424 mature microRNAs have been reported and more than 2500 mature miRNAs have been discovered in mammalian systems [7]. Many studies observed elevated levels of miRNAs in the circulation from breast cancer patients, such as miR-21 [8], miR-20b-5p [9], miR-34a [10] [11] [12], miR-133a [13] [14], miR-145 [15], miR-181a [16], miR-424 [17], miR-801 [18] [19], and so on [20] [26]. According to the GEN-CODE analysis 27817 transcripts originating from 15931 genes can be identified as lncRNAs [27].…”

A Lamping U-Shaped Fiber Biosensor Detector for MicroRNA

“…In humans, over 1000 miRNAs have been identified, and each miRNA potentially represses hundreds of target mRNAs [3]. Over the last several decades, there have been numerous studies that have found associations between miRNAs and various types of cancer, such as lymphocytic leukemia [4,5], lung cancer [6,7], colorectal neoplasia [8], Burkitt lymphoma [9], glioblastoma [10], tumor cell [11], B cell lymphomas of hepatocellular carcinoma (HCC) [12], oral squamous cell carcinoma [13], and breast cancer [14]. Relatedly, many biological techniques have been developed for miRNA detectors, including Northern blot [15], real-time PCR [16], oligonucleotide microarray [17,18], laser-induced fluorescence [19], microarray [20,21], and even various label-free techniques [22], as well as some strategy approaches for the detection of miRNAs, such as electrochemical, photoelectrochemical and optical fiber sensing methods.…”